Efficacy and safety of tumor treating fields (TTF) combined with chemotherapy versus chemotherapy only in the treatment of glioblastoma: a systematic review and meta-analysis - Scorecard - MDSpire
Advertisement
Efficacy and safety of tumor treating fields (TTF) combined with chemotherapy versus chemotherapy only in the treatment of glioblastoma: a systematic review and meta-analysis
Clinical Scorecard: Assessment of the Safety and Effectiveness of Tumor Treating Fields (TTF) in Combination with Chemotherapy Versus Chemotherapy Alone for Glioblastoma: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Glioblastoma (GBM)
Key Mechanisms
Tumor treating fields (TTF) interfere with tumor cell division and proliferation, potentially enhancing chemosensitivity.
Target Population
Individuals with newly diagnosed and recurrent glioblastoma.
Care Setting
Oncology clinics and hospitals providing chemotherapy.
Key Highlights
TTF combined with chemotherapy significantly improves progression-free survival (PFS) and overall survival (OS) in GBM patients.
No significant difference in systemic adverse events between TTF and chemotherapy alone.
Increased incidence of skin irritation observed in the TTF cohort.
Meta-analysis included 14 studies with 2,376 participants.
TTF represents a promising alternative treatment modality for GBM.
Guideline-Based Recommendations
Diagnosis
Diagnosis of GBM should follow established imaging and histopathological criteria.
Management
Consider TTF in conjunction with standard chemotherapy for newly diagnosed and recurrent GBM patients.
Monitoring & Follow-up
Monitor for skin irritation and other adverse effects in patients receiving TTF.
Risks
Be aware of the potential for increased skin irritation with TTF therapy.
Patient & Prescribing Data
Patients with newly diagnosed and recurrent glioblastoma.
TTF combined with chemotherapy may enhance survival outcomes without increasing systemic toxicity.
Clinical Best Practices
Utilize TTF as an adjunct to standard chemotherapy in GBM treatment protocols.
Regularly assess patient tolerance to TTF, particularly regarding skin reactions.
